The cash flow of MBX Biosciences, Inc. over the past 3 years
Chart MBX Biosciences, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2023–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, MBX Biosciences, Inc.'s operating cash flow was -$79.95M and its capital expenditures $1.93M, leaving free cash flow of -$81.88M. Free cash flow was below zero in all 3 years shown. It ranged from -$81.88M in fiscal 2025 to -$32.11M in fiscal 2023. Capital expenditures were highest in fiscal 2025, at $1.93M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$79.95M | $1.93M | -$81.88M |
| 2024ended Dec 31, 2024 | -$54.68M | $874K | -$55.55M |
| 2023ended Dec 31, 2023 | -$31.98M | $129K | -$32.11M |
Fiscal years as MBX Biosciences, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on MBX Biosciences, Inc.
- The profitability of MBX Biosciences, Inc.
- The debt of MBX Biosciences, Inc.
- All of MBX Biosciences, Inc.'s financials, charted
Companies of a similar size
- LBTYALiberty Global Ltd.
- GPKGraphic Packaging Holding Co
- BFAMBRIGHT HORIZONS FAMILY SOLUTIONS INC.
- PATKPATRICK INDUSTRIES INC
- DXDYNEX CAPITAL, INC.
Not investment advice. This page shows what MBX Biosciences, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.